Dosimetry results of Oncolym™ in the treatment of refractory B-cell non-Hodgkin's lymphoma (NHL).

被引：0
|
作者：
Verkh, LI
Murray, JL
Kripas, CJ
Wessels, BW
Varma, VM
Kahn, D
Bushnell, DL
Serafini, AN
Oliver, JC
机构：
[1] Alpha Therapeut Corp, Los Angeles, CA 90032 USA
[2] MD Anderson, Houston, TX USA
[3] Cornell Univ, Ithaca, NY 14853 USA
[4] George Washington Med Ctr, Washington, DC USA
[5] Iowa City Vet Adm, Iowa City, IA USA
[6] Univ Miami, Miami, FL 33152 USA
来源：
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 1998年 / 13卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
49
引用
收藏
页码：66 / 66
页数：1
相关论文
共 50 条
  • [41] Overt B-cell non-Hodgkin's lymphoma (B-NHL): Role of hepatitis C virus (HCV).
    Germanidis, G
    Haioun, C
    Gaulard, P
    Reyes, F
    Dhumeaux, D
    Pawlotsky, JM
    HEPATOLOGY, 1999, 30 (04) : 605A - 605A
  • [42] Overt B-cell non-Hodgkin's lymphoma (B-NHL):: Role of hepatitis C virus (HCV)
    Germanidis, G
    Haioun, C
    Gaulard, P
    Castéra, L
    Reyes, F
    Dhumeaux, D
    Pawlotsky, JM
    JOURNAL OF HEPATOLOGY, 2000, 32 : 99 - 99
  • [43] Phase I study of bendamustine combined with rituximab in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL)
    Taniwaki, M.
    Ogura, M.
    Matsumoto, Y.
    Uchida, T.
    Ohmachi, K.
    Ando, K.
    Watanabe, T.
    Tobinai, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] The GMALL-B-ALL/NHL protocol is an effective salvage treatment in relapsed and refractory aggressive B-cell non-Hodgkin's lymphomas
    Sakarou, M.
    Duehrsen, U.
    Huettmann, A.
    ONKOLOGIE, 2012, 35 : 40 - 40
  • [45] Lisocabtagene Maraleucel (Liso-Cel) Treatment of Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma and Secondary CNS Lymphoma: Initial Results From TRANSCEND NHL 001
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 19 - 20
  • [46] A pilot study of combined therapy with rituximab (R) and epoch in refractory or relapsed diffuse large B-cell Non-Hodgkin's Lymphoma (NHL).
    Aung, S
    Krishnan, J
    Lessin, L
    Priebat, D
    Sharma, D
    Malkovska, V
    BLOOD, 1999, 94 (10) : 257B - 257B
  • [47] Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma
    Liu, Yang
    Li, Yanju
    Zhang, Chike
    Yang, Xu
    Yang, Bo
    Cheng, Jinyang
    Chen, Juan
    Yuan, Xiaoshuang
    Li, Ya
    Chen, Ying
    Zhang, Fengqi
    Tang, Dongxin
    He, Zhixu
    Wang, Feiqing
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [48] New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma
    Burton, Jack D.
    Goldenberg, David M.
    EXPERT OPINION ON EMERGING DRUGS, 2010, 15 (04) : 569 - 583
  • [49] Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL).
    Witzig, TE
    Gordon, LI
    Wiseman, GA
    Spies, S
    Emmanouilides, C
    Czuczman, MS
    Flinn, IW
    Barlett, NL
    Murray, JL
    Alkuzweny, B
    Multani, PS
    Grillo-López, AJ
    White, CA
    BLOOD, 2000, 96 (11) : 731A - 731A
  • [50] Zevalin™ radioimmunotherapy can be safely administered to patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL).
    Witzig, TE
    White, CA
    Gordon, LI
    Wiseman, GA
    Emmanouilides, C
    Murray, JL
    Lister, J
    Multani, PS
    BLOOD, 2001, 98 (11) : 606A - 606A
12345